- Home
- MTNB vs CERO Comparison
MTNB vs CERO Comparison
Compare MTNB & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- CERO
- Stock Information
- Founded
- MTNB 2013
- CERO 2017
- Country
- MTNB United States
- CERO United States
- Employees
- MTNB N/A
- CERO N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- MTNB Health Care
- CERO
- Exchange
- MTNB Nasdaq
- CERO Nasdaq
- Market Cap
- MTNB 3.6M
- CERO 3.5M
- IPO Year
- MTNB N/A
- CERO N/A
- Fundamental
- Price
- MTNB $0.91
- CERO $9.56
- Analyst Decision
- MTNB Hold
- CERO Strong Buy
- Analyst Count
- MTNB 1
- CERO 2
- Target Price
- MTNB N/A
- CERO $45.00
- AVG Volume (30 Days)
- MTNB 552.6K
- CERO 3.3M
- Earning Date
- MTNB 08-13-2025
- CERO 08-13-2025
- Dividend Yield
- MTNB N/A
- CERO N/A
- EPS Growth
- MTNB N/A
- CERO N/A
- EPS
- MTNB N/A
- CERO N/A
- Revenue
- MTNB N/A
- CERO N/A
- Revenue This Year
- MTNB N/A
- CERO N/A
- Revenue Next Year
- MTNB N/A
- CERO N/A
- P/E Ratio
- MTNB N/A
- CERO N/A
- Revenue Growth
- MTNB N/A
- CERO N/A
- 52 Week Low
- MTNB $0.47
- CERO $6.71
- 52 Week High
- MTNB $9.60
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- MTNB 55.61
- CERO 47.92
- Support Level
- MTNB $0.83
- CERO $8.12
- Resistance Level
- MTNB $0.95
- CERO $13.14
- Average True Range (ATR)
- MTNB 0.11
- CERO 2.69
- MACD
- MTNB -0.01
- CERO 0.37
- Stochastic Oscillator
- MTNB 28.64
- CERO 14.05
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.